Economic Implication of Targeting Higher Trough Level with Extended Half-Life FVIII Prophylaxis
Farmeconomia. Health Economics and Therapeutic Pathways · 12.03.2026 · 27 (1)
DOI: 10.7175/fe.v27i1.1604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Farmeconomia. Health Economics and Therapeutic Pathways, online erschienen am 12.03.2026. Verfasst von Carla Fornari und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
AIM: This analysis aimed to assess the annual International Unit (IU) consumption and costs of prophylaxis therapies with extended half-life recombinant FVIII (EHL-rFVIII), targeting a traditional trough level of 1% and the higher levels of 3% and 5% recommended by recent guidelines and expert consensus, using a theoretical pharmacokinetic model. METHODS: A pharmacokinetic model was developed to calculate annual treatment IU consumption and costs of EHL-rFVIII products to sustain different trough levels (1%, 3% and 5%) in adult patients with hemophilia A in Italy. The model assumed a one-year perspective and assessed two scenarios: one with lower frequency of administration and one with higher frequency. RESULTS: The related annual treatment per-patient cost increased as the trough level increased. The per-patient annual cost was €117,811 to achieve a trough level of 1%, €351,543 to achieve a 3% trough level and €585,905 to achieve a 5% trough level. The increase in dose frequency (alternative scenario), that is the reduction of time between infusions, reduced the estimated doses to achieve the pre-defined FVIII levels. CONCLUSIONS: These results suggest the need for further discussion about the trough levels to target with the actual EHL-rFVIII and the prophylaxis dose and regimen selection for each patient, also considering all treatment options available and the economic implications.
Zitieren
APA
Fornari, C., Antonacci, S., Stoppa, S., Mantovani, L. G., Castaman, G., & Cortesi, P. A. (2026). Economic Implication of Targeting Higher Trough Level with Extended Half-Life FVIII Prophylaxis. Farmeconomia. Health Economics and Therapeutic Pathways, 27(1). https://doi.org/10.7175/fe.v27i1.1604
Vancouver
Fornari C, Antonacci S, Stoppa S, Mantovani LG, Castaman G, Cortesi PA. Economic Implication of Targeting Higher Trough Level with Extended Half-Life FVIII Prophylaxis. Farmeconomia. Health Economics and Therapeutic Pathways. 2026;27(1). doi:10.7175/fe.v27i1.1604
BibTeX
@article{Fornari2026,
author = {Fornari, Carla and Antonacci, Stefania and Stoppa, Stefano and Mantovani, Lorenzo Giovanni and Castaman, Giancarlo and Cortesi, Paolo Angelo},
title = {Economic Implication of Targeting Higher Trough Level with Extended Half-Life FVIII Prophylaxis},
journal = {Farmeconomia. Health Economics and Therapeutic Pathways},
year = {2026},
volume = {27},
number = {1},
doi = {10.7175/fe.v27i1.1604}
}
EUVIMED